Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Patanjali's 'Dhoka' Chyawanprash Ad BANNED! Delhi High Court Rules for Dabur India in Major Legal Win!

Consumer Products

|

Updated on 11 Nov 2025, 05:45 am

Whalesbook Logo

Reviewed By

Satyam Jha | Whalesbook News Team

Short Description:

The Delhi High Court has temporarily banned Patanjali Ayurved and Patanjali Foods from running their advertisement that labelled rival Chyawanprash products as "Dhoka" (deception). The order came after Dabur India Limited filed a plea, arguing the ad disparaged their popular Dabur Chyawanprash and the broader category of Ayurvedic formulations. The court found the advertisement prima facie constituted commercial disparagement, going beyond permissible advertising claims.
Patanjali's 'Dhoka' Chyawanprash Ad BANNED! Delhi High Court Rules for Dabur India in Major Legal Win!

▶

Stocks Mentioned:

Dabur India Limited
Patanjali Foods Limited

Detailed Coverage:

The Delhi High Court has issued an interim injunction restraining Patanjali Ayurved Limited and Patanjali Foods Limited from broadcasting or publishing advertisements that describe other Chyawanprash products as "Dhoka" (deception). This significant ruling stems from a lawsuit filed by Dabur India Limited, which contended that Patanjali's commercial unfairly disparaged its flagship Dabur Chyawanprash and the entire segment of similar Ayurvedic formulations.

Justice Tejas Karia, presiding over the case, noted that the advertisement seemed to universally disparage all competing Chyawanprash brands, including Dabur, which holds a substantial market share. The court explicitly stated that labelling all other Chyawanprash as "Dhoka" or deception amounts to commercial disparagement and is not acceptable, even with creative liberty. Patanjali's defense that the ad was mere "puffery and hyperbole" was rejected, as the court recognized that such generic disparagement harms market leaders and constitutes unfair competition. Consequently, Patanjali has been ordered to cease airing the ad and remove it from all digital platforms, including YouTube and Instagram, within 72 hours. The next hearing is scheduled for February 26, 2026.

Impact: This legal victory for Dabur India could bolster its market confidence and potentially influence Patanjali's advertising strategies moving forward. It sets a precedent for fair competition in the FMCG sector regarding comparative advertising and product disparagement. Investors in the consumer goods sector should monitor how these competitive dynamics evolve. Rating: 6/10

Difficult Terms: * **Chyawanprash**: A traditional Ayurvedic herbal jam or paste, known for its health benefits. * **Commercial Disparagement**: An act of damaging the reputation of a business or its products by making false or misleading statements. * **Puffery**: Exaggerated claims made in advertising that are generally considered opinion rather than fact and are not legally actionable. * **Comparative Advertising**: Advertising that compares one brand or product with another. * **Interim Injunction**: A temporary court order issued to prevent irreparable harm to a party before the final determination of a case. * **Prima Facie Case**: A case in which there is enough evidence to proceed to trial, appearing to be true on first impression. * **Ayurvedic Formulations**: Products or preparations based on the ancient Indian system of medicine, Ayurveda.


Crypto Sector

US Crypto Power Play: Senators Propose Massive Shift from SEC to CFTC!

US Crypto Power Play: Senators Propose Massive Shift from SEC to CFTC!

US Crypto Power Play: Senators Propose Massive Shift from SEC to CFTC!

US Crypto Power Play: Senators Propose Massive Shift from SEC to CFTC!


Healthcare/Biotech Sector

Torrent Pharma: Buy Signal Issued! Rs 4200 Target & Strategic JB Chemicals Deal Unveiled!

Torrent Pharma: Buy Signal Issued! Rs 4200 Target & Strategic JB Chemicals Deal Unveiled!

Medanta Q2 SHOCKER! Record Profits & Massive Expansion Plans Ignite Investor Frenzy!

Medanta Q2 SHOCKER! Record Profits & Massive Expansion Plans Ignite Investor Frenzy!

Lupin Stock BOOM? Nomura REVEALS 30% Upside Target & Buy Signal – What You MUST Know!

Lupin Stock BOOM? Nomura REVEALS 30% Upside Target & Buy Signal – What You MUST Know!

Torrent Pharma's Bold New Strategy: Weight Loss Drugs, US Expansion, and Massive Acquisitions Set to Skyrocket Growth!

Torrent Pharma's Bold New Strategy: Weight Loss Drugs, US Expansion, and Massive Acquisitions Set to Skyrocket Growth!

Torrent Pharma: Buy Signal Issued! Rs 4200 Target & Strategic JB Chemicals Deal Unveiled!

Torrent Pharma: Buy Signal Issued! Rs 4200 Target & Strategic JB Chemicals Deal Unveiled!

Medanta Q2 SHOCKER! Record Profits & Massive Expansion Plans Ignite Investor Frenzy!

Medanta Q2 SHOCKER! Record Profits & Massive Expansion Plans Ignite Investor Frenzy!

Lupin Stock BOOM? Nomura REVEALS 30% Upside Target & Buy Signal – What You MUST Know!

Lupin Stock BOOM? Nomura REVEALS 30% Upside Target & Buy Signal – What You MUST Know!

Torrent Pharma's Bold New Strategy: Weight Loss Drugs, US Expansion, and Massive Acquisitions Set to Skyrocket Growth!

Torrent Pharma's Bold New Strategy: Weight Loss Drugs, US Expansion, and Massive Acquisitions Set to Skyrocket Growth!